Neurodegeneration is the progressive loss of neuronal structure and function that characterizes a group of devastating chronic diseases: Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, a… Read more.
17 factors with evidence, ordered from highest to lowest effectiveness. Information, not medical advice.
⏱ 3 min read
Neurodegeneration is the progressive loss of neuronal structure and function that characterizes a group of devastating chronic diseases: Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, multiple system atrophy, progressive supranuclear palsy, frontotemporal dementia, among others. Although each disease has its own specific clinical and mechanistic profile, they share several common therapeutic targets (oxidative stress, mitochondrial dysfunction, neuroinflammation, abnormal protein aggregation, dysfunction of the autophagy-lysosomal system) and benefit from preventive and trajectory-modifying strategies that overlap considerably.
All major neurodegenerative diseases share, to varying degrees:
This mechanistic convergence explains why interventions that act on these processes can have effects across multiple diseases.
Epidemiological data suggest that approximately 30-40% of dementia risk (especially Alzheimer's) is attributable to modifiable factors across the life course. The best-supported interventions are the same ones that protect cardiovascular and metabolic health:
B vitamins (folate, B12, B6) in people with elevated homocysteine: the VITACOG trial showed a significant reduction in brain atrophy with this combination.
Omega-3 EPA/DHA: DHA is a major structural component of neuronal membranes; adequate intakes are associated with a lower incidence of dementia.
Vitamin D: subclinical deficiencies are associated with poorer cognition.
Coenzyme Q10 (ubiquinol): support in early Parkinson's (modest).
Creatine: modest support in mitochondrial conditions and general neuroprotection.
Lion's mane (Hericium erinaceus): the Mori 2009 trial showed improvements in mild cognitive impairment; stimulates NGF in preclinical studies.
Spermidine: with favorable epidemiological data and preliminary clinical studies in mild cognitive impairment.
Mitoquinol, MitoQ: aimed at mitochondrial health.
Urolithin A: with growing data on mitophagy.
Curcumin, resveratrol, EGCG: extensive preclinical support, modest clinical data.
Citicoline and alpha-GPC: support in vascular cognitive impairment and as an adjunct in Alzheimer's.
Mucuna pruriens (pharmacological caution): provides L-DOPA, relevant specifically in Parkinson's as an adjunct or alternative to levodopa.
During deep sleep, the brain's glymphatic system increases its activity 10-20-fold, clearing toxic metabolites including beta-amyloid. Chronic sleep deprivation is associated with accelerated amyloid accumulation in prospective cohorts. Good-quality sleep is probably one of the most underrated neuroprotective interventions.
Significant and progressive cognitive complaints, resting tremor, rigidity, gait disturbances, progressive muscle weakness, progressive language disturbances, and significant personality or behavioral changes require neurological evaluation for early diagnosis. Anti-amyloid monoclonal antibodies for early Alzheimer's (aducanumab, lecanemab, donanemab) and other disease-modifying therapies are under active development and require specialized evaluation.
Preventing neurodegeneration is one of the areas where lifestyle sustained over decades has the greatest potential impact: regular aerobic exercise, Mediterranean diet, cardiovascular control, good-quality sleep, continuous cognitive stimulation, active social ties. Specific supplements (B-complex in high homocysteine, omega-3, lion's mane in mild cognitive impairment, spermidine) have modest support and are useful adjuncts. In established neurodegenerative diseases, specialized medical treatment is the foundation; supplements are adjuncts with modest expectations. Research is active and new options (anti-amyloid, others) are appearing that are redefining the landscape.
⏱ 3 min read
Neurodegeneration is the progressive loss of neuronal structure and function that characterizes a group of devastating chronic diseases: Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, multiple system atrophy, progressive supranuclear palsy, frontotemporal dementia, among others. Although each disease has its own specific clinical and mechanistic profile, they share several common therapeutic targets (oxidative stress, mitochondrial dysfunction, neuroinflammation, abnormal protein aggregation, dysfunction of the autophagy-lysosomal system) and benefit from preventive and trajectory-modifying strategies that overlap considerably.
All major neurodegenerative diseases share, to varying degrees:
This mechanistic convergence explains why interventions that act on these processes can have effects across multiple diseases.
Epidemiological data suggest that approximately 30-40% of dementia risk (especially Alzheimer's) is attributable to modifiable factors across the life course. The best-supported interventions are the same ones that protect cardiovascular and metabolic health:
B vitamins (folate, B12, B6) in people with elevated homocysteine: the VITACOG trial showed a significant reduction in brain atrophy with this combination.
Omega-3 EPA/DHA: DHA is a major structural component of neuronal membranes; adequate intakes are associated with a lower incidence of dementia.
Vitamin D: subclinical deficiencies are associated with poorer cognition.
Coenzyme Q10 (ubiquinol): support in early Parkinson's (modest).
Creatine: modest support in mitochondrial conditions and general neuroprotection.
Lion's mane (Hericium erinaceus): the Mori 2009 trial showed improvements in mild cognitive impairment; stimulates NGF in preclinical studies.
Spermidine: with favorable epidemiological data and preliminary clinical studies in mild cognitive impairment.
Mitoquinol, MitoQ: aimed at mitochondrial health.
Urolithin A: with growing data on mitophagy.
Curcumin, resveratrol, EGCG: extensive preclinical support, modest clinical data.
Citicoline and alpha-GPC: support in vascular cognitive impairment and as an adjunct in Alzheimer's.
Mucuna pruriens (pharmacological caution): provides L-DOPA, relevant specifically in Parkinson's as an adjunct or alternative to levodopa.
During deep sleep, the brain's glymphatic system increases its activity 10-20-fold, clearing toxic metabolites including beta-amyloid. Chronic sleep deprivation is associated with accelerated amyloid accumulation in prospective cohorts. Good-quality sleep is probably one of the most underrated neuroprotective interventions.
Significant and progressive cognitive complaints, resting tremor, rigidity, gait disturbances, progressive muscle weakness, progressive language disturbances, and significant personality or behavioral changes require neurological evaluation for early diagnosis. Anti-amyloid monoclonal antibodies for early Alzheimer's (aducanumab, lecanemab, donanemab) and other disease-modifying therapies are under active development and require specialized evaluation.
Preventing neurodegeneration is one of the areas where lifestyle sustained over decades has the greatest potential impact: regular aerobic exercise, Mediterranean diet, cardiovascular control, good-quality sleep, continuous cognitive stimulation, active social ties. Specific supplements (B-complex in high homocysteine, omega-3, lion's mane in mild cognitive impairment, spermidine) have modest support and are useful adjuncts. In established neurodegenerative diseases, specialized medical treatment is the foundation; supplements are adjuncts with modest expectations. Research is active and new options (anti-amyloid, others) are appearing that are redefining the landscape.